James Buteau

1 month ago | jnm.snmjournals.org | David Chen |James Buteau |Louise Emmett |Ramin Alipour

The current prevalence of low intraprostatic uptake for staging prostate-specific membrane antigen (PSMA) PET ranges between 4.4% and 17% in retrospective studies. We aimed to define the prevalence and describe the outcomes of patients with low intraprostatic uptake on PSMA PET/CT in the prospective proPSMA study. Methods: We identified patients with an SUV of 4 or less on PSMA PET/CT in the proPSMA study. Patients were followed up until 42 mo after randomization.